These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30019101)

  • 81. Combination trans arterial chemoembolization (TACE) plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review of the literature.
    Abdel-Rahman O; Elsayed ZA
    Dig Dis Sci; 2013 Dec; 58(12):3389-96. PubMed ID: 24046163
    [TBL] [Abstract][Full Text] [Related]  

  • 82. The efficacy of TACE combined sorafenib in advanced stages hepatocellullar carcinoma.
    Qu XD; Chen CS; Wang JH; Yan ZP; Chen JM; Gong GQ; Liu QX; Luo JJ; Liu LX; Liu R; Qian S
    BMC Cancer; 2012 Jun; 12():263. PubMed ID: 22721173
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
    Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
    Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
    Zhang W; Zhao G; Wei K; Zhang Q; Ma W; Wu Q; Zhang T; Kong D; Li Q; Song T
    Med Oncol; 2015 Apr; 32(4):107. PubMed ID: 25750040
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective comparison with previously known prognostic models.
    Baek KK; Kim JH; Uhm JE; Park SH; Lee J; Park JO; Park YS; Kang WK; Lim HY
    Oncology; 2011; 80(3-4):167-74. PubMed ID: 21701230
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation.
    Invernizzi F; Iavarone M; Zavaglia C; Mazza S; Maggi U; Cesarini L; Antonelli B; Airoldi A; Manini MA; Sangiovanni A; Rossi G; Donato MF; Saverio Belli L; Lampertico P
    Transplantation; 2020 Mar; 104(3):568-574. PubMed ID: 31517781
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Baseline Interleukin-6 and -8 predict response and survival in patients with advanced hepatocellular carcinoma treated with sorafenib monotherapy: an exploratory post hoc analysis of the SORAMIC trial.
    Öcal O; Schütte K; Kupčinskas J; Morkunas E; Jurkeviciute G; de Toni EN; Ben Khaled N; Berg T; Malfertheiner P; Klümpen HJ; Sengel C; Basu B; Valle JW; Benckert J; Gasbarrini A; Palmer D; Seidensticker R; Wildgruber M; Sangro B; Pech M; Ricke J; Seidensticker M
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):475-485. PubMed ID: 33855585
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.
    Merle P; Blanc JF; Phelip JM; Pelletier G; Bronowicki JP; Touchefeu Y; Pageaux G; Gerolami R; Habersetzer F; Nguyen-Khac E; Casadei-Gardini A; Borbath I; Tran A; Wege H; Saad AS; Colombo M; Abergel A; Richou C; Waked I; Yee NS; Molé A; Attali P; Le Boulicaut J; Vasseur B;
    Lancet Gastroenterol Hepatol; 2019 Jun; 4(6):454-465. PubMed ID: 30954567
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study.
    Lee S; Kim BK; Kim SU; Park SY; Kim JK; Lee HW; Park JY; Kim DY; Ahn SH; Tak WY; Kweon YO; Lee JI; Lee KS; Kim HJ; Han KH
    J Gastroenterol Hepatol; 2014; 29(7):1463-9. PubMed ID: 25273508
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Sorafenib for Treatment of Hepatocellular Carcinoma: A Survival Analysis From the South American Liver Research Network.
    Leathers JS; Balderramo D; Prieto J; Diehl F; Gonzalez-Ballerga E; Ferreiro MR; Carrera E; Barreyro F; Diaz-Ferrer J; Singh D; Mattos AZ; Carrilho F; Debes JD
    J Clin Gastroenterol; 2019 Jul; 53(6):464-469. PubMed ID: 29952857
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Antiviral therapy in the improvement of survival of patients with hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
    Xu L; Gao H; Huang J; Wang H; Zhou Z; Zhang Y; Li S; Chen M
    J Gastroenterol Hepatol; 2015 Jun; 30(6):1032-9. PubMed ID: 25639513
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.
    Llovet JM; Decaens T; Raoul JL; Boucher E; Kudo M; Chang C; Kang YK; Assenat E; Lim HY; Boige V; Mathurin P; Fartoux L; Lin DY; Bruix J; Poon RT; Sherman M; Blanc JF; Finn RS; Tak WY; Chao Y; Ezzeddine R; Liu D; Walters I; Park JW
    J Clin Oncol; 2013 Oct; 31(28):3509-16. PubMed ID: 23980090
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Volumetric assessment of tumour response using functional MR imaging in patients with hepatocellular carcinoma treated with a combination of doxorubicin-eluting beads and sorafenib.
    Corona-Villalobos CP; Halappa VG; Geschwind JF; Bonekamp S; Reyes D; Cosgrove D; Pawlik TM; Kamel IR
    Eur Radiol; 2015 Feb; 25(2):380-90. PubMed ID: 25226843
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial.
    Pinyol R; Montal R; Bassaganyas L; Sia D; Takayama T; Chau GY; Mazzaferro V; Roayaie S; Lee HC; Kokudo N; Zhang Z; Torrecilla S; Moeini A; Rodriguez-Carunchio L; Gane E; Verslype C; Croitoru AE; Cillo U; de la Mata M; Lupo L; Strasser S; Park JW; Camps J; Solé M; Thung SN; Villanueva A; Pena C; Meinhardt G; Bruix J; Llovet JM
    Gut; 2019 Jun; 68(6):1065-1075. PubMed ID: 30108162
    [TBL] [Abstract][Full Text] [Related]  

  • 96. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Staufer K; Fischer L; Seegers B; Vettorazzi E; Nashan B; Sterneck M
    Transpl Int; 2012 Nov; 25(11):1158-64. PubMed ID: 22882364
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events.
    Rimola J; Díaz-González Á; Darnell A; Varela M; Pons F; Hernandez-Guerra M; Delgado M; Castroagudin J; Matilla A; Sangro B; Rodriguez de Lope C; Sala M; Gonzalez C; Huertas C; Minguez B; Ayuso C; Bruix J; Reig M
    Hepatology; 2018 Feb; 67(2):612-622. PubMed ID: 28898447
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Sorafenib therapy in advanced hepatocellular carcinoma: the SHARP trial.
    Rimassa L; Santoro A
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):739-45. PubMed ID: 19496710
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Impact of psoas muscle index assessed by a simple measurement method on tolerability and duration of continued treatment with sorafenib in hepatocellular carcinoma patients.
    Ogushi K; Chuma M; Numata K; Nozaki A; Moriya S; Uojima H; Kondo M; Morimoto M; Maeda S
    Eur J Gastroenterol Hepatol; 2022 Jul; 34(7):774-781. PubMed ID: 35102114
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Outcomes of Acitretin Treatment for Refractory Multikinase Inhibitor-Induced Hand-Foot Skin Reaction.
    Said JT; Singer S; Iannattone L; Sauder M; LeBoeuf NR
    JAMA Dermatol; 2022 Jul; 158(7):824-826. PubMed ID: 35544124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.